- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02164279
Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children (peeDIAB2)
Identification and First Validation of Early Non-invasive Biomarkers of Diabetic Nephropathy in Type I Diabetic Children
About 30 to 40% of patients suffering from type I diabetes are at risk of developing a diabetic nephropathy (DN) leading more or less rapidly to an end-stage renal disease. Nowadays, the microalbuminuria is the most often used clinical parameter for possible onset of DN. However, it is a late (because it permits to detect a renal disease already present), non-specific and low sensitive biomarker.
Therefore the main objective of this study is to identify early urinary biomarkers predictive of DN in children with type I diabetes, before the appearance of a microalbuminuria.
Study Overview
Status
Intervention / Treatment
Detailed Description
Once the type I diabetes is diagnosed, the speed of progression to a DN is very variable. Thus, the discovery of biomarkers able to distinguish progressor patients from non-progressor since the appearance of a microalbuminuria, is crucial in order to take care of progressor patients the earlier and to slow down the disease progression.
The investigators have shown that urine is a biological sample extremely well suited for proteome analysis with the aim to identify biomarkers of renal damages. Indeed, they were the first to analyze the urinary proteome of infant using capillary electrophoresis-coupled mass spectrometry. This technic permits to analyse the entire urinary proteome of a person in one hour.
Several laboratories tried to identify other predictive urinary biomarkers of the development of a DN in diabetic patients, but with limited success and nowadays in the clinical practice they still use the measure of the microalbuminuria. Contrary to precedent studies, the investigators develop an analysis without a priori and starting with early samples (without any signs of DN) associating the urinary peptide profile with the DN progression over 9-10 years.
This is a nested case-control study in a cohort of 317 patients constituting the urinary biological collection. (The urinary samples of a type I diabetic cohort of 317 patients seen between 2004 and 2008 have been collected.) These patients will be contacted at the end of 2012 to obtain a number of participation of 180 patients authorizing the use aposteriori of their urinary samples. Among this cohort, the investigators evaluate at 90 the number of patients with a DN defined by a dosage of microalbuminuria higher than 100 mg/L.
The primary endpoint of this study is therefore the identification of urinary biomarkers predictive of DN in type I diabetes pediatric patients.
The secondary endpoints are :
- The estimation of sensibility and specificity parameters, and the Area Under the Curve (AUC).
- The identification of factors associated with the variability of biomarkers expression such as the age at the moment of the diagnosis, the time between the diagnosis and the urinary collection, the rate of microalbuminuria, and the type of insulin used by the patient.
- And in the subgroup of patients for whom two urinary samples have been collected, the investigators want to study the urinary proteome stability in patients with no DN in 2013.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Toulouse, France, 31059
- Purpan Children Hospital
-
Toulouse, France, 31059
- Rangueil hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient with a type I diabetes diagnosed before 15 years-old
- Urinary collection done 5 years after the diagnosis
- Urinary collection done without any acute intermittent pathology
- Urinary collection done without any treatment (other than diabetes treatment)
- Glomerular filtration rate ≥ 60 mL/min at the moment of the urinary collection already done
- Informed consent obtained aposteriori for the analysis of the urinary samples collected between 2004 and 2008, and consent obtained for the analysis of urinary sample collected in 2013
Exclusion Criteria:
- Patients suffering from an autoimmune disease associated with the diabetes (vitiligo, Grave's disease, thyroiditis, pernicious anemia or Biermer's disease)
- Patient with a renal disease (other than diabetic nephropathy) at the first urinary collection (between 2004 and 2008)
- Pregnancy, because the urinary proteome and the microalbumin dosage can be modified during a pregnancy.
- Patient refusal to use urinary samples already collected
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Progressor (ND)
Group of patients with an albuminuria > 100mg/L, by Urinary sample collection
|
urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( < or > than 100mg/L)
|
Non-Progressor (non-ND)
Group of patients without an albuminuria > 100mg/L, by Urinary sample collection
|
urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( < or > than 100mg/L)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify predictive non-invasive urinary biomarkers
Time Frame: Baseline (Inclusion day)
|
Urinary samples collection Assessment of the microalbuminuria to diagnose the diabetic nephropathy (DN)
|
Baseline (Inclusion day)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relation of urinary markers with patient characteristics
Time Frame: Baseline (Inclusion day)
|
Patients characteristics : age of the patients at the diabetes diagnosis, their age at the urinary collection, their sex, the time between the diagnosis and the urinary collection, the type of insulin used.
|
Baseline (Inclusion day)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephane DECRAMER, PhD, Toulouse University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12 356 03
- 2012-A01097-36 (Registry Identifier: ID-RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus With Diabetic Nephropathy
-
Steno Diabetes Center CopenhagenCompletedType 1 Diabetes Mellitus With Diabetic NephropathyDenmark
-
University Medical Center GroningenJuvenile Diabetes Research Foundation; Lexicon PharmaceuticalsNot yet recruitingType 1 Diabetes Mellitus With Diabetic NephropathyNetherlands, United States, Canada, Denmark, Finland
-
University of Colorado, DenverCompletedDiabetes Mellitus, Type 1 | Diabetic Nephropathies | Type 1 Diabetes Mellitus | Diabetes Mellitus Complication | Nephropathy | Autoimmune Diabetes | Juvenile DiabetesUnited States
-
University of SydneyNational Health and Medical Research Council, Australia; Mylan Pharmaceuticals... and other collaboratorsRecruitingDiabetic Retinopathy | Diabetic Nephropathies | Type 1 Diabetes MellitusAustralia, Hong Kong, New Zealand
-
Akebia TherapeuticsCyclerion TherapeuticsCompletedType 2 Diabetes Mellitus With Diabetic NephropathyUnited States
-
Tianjin Medical University General HospitalCompletedType 2 Diabetes Mellitus With Diabetic NephropathyChina
-
University Hospital, GrenobleCompletedDiabetic Nephropathy | Type 1 Diabetes MellitusFrance
-
Calliditas Therapeutics ABCompletedType 2 Diabetes Mellitus With Diabetic NephropathyAustralia, United States, Germany, Poland, Canada, Czech Republic
-
Peter RossingCompletedType 1 Diabetes | Diabetic NephropathyDenmark
-
Ain Shams UniversityCompletedRole of Carnosine as an Adjuvant Therapy for Diabetic Nephropathy in Pediatrics With Type 1 DiabetesType 1 Diabetes | Diabetic Nephropathy | Oxidative Stress | Carnosine
Clinical Trials on Urinary sample collection
-
University Hospital, ToursNot yet recruitingRenal Transplant | ConversionFrance
-
Centre Hospitalier Universitaire de Saint EtienneRecruitingClear Cell Renal Cell CarcinomaFrance
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Recruiting
-
Masonic Cancer Center, University of MinnesotaCompletedAcute Leukemia | Chemotherapy-Induced Gut Barrier DamageUnited States
-
Poitiers University HospitalRecruitingPsoriasis | Psoriatic ArthritisFrance
-
Institut PasteurCentre Médical de l'Institut PasteurRecruiting
-
Emory UniversityMichael J. Fox Foundation for Parkinson's ResearchCompletedDefining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative ProcessesParkinson's DiseaseUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)RecruitingCancerUnited States
-
Institut PasteurBiogroup Laboratoire de biologie médicaleRecruiting